Who is sponsoring NCT00870103?

NCT00870103 is sponsored by Alcon Research.

What drugs are being tested in NCT00870103?

Interventions: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops.

What is the status of NCT00870103?

NCT00870103 is currently COMPLETED.

Last reviewed 2010-03-03 · How we verify

An Evaluation of the Prophylactic Efficacy and Safety of the Administration of the Combination Formulation of Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops in Inflammation and Infection Post-cataract Surgery

NCT00870103 Phase 4 COMPLETED Results posted

To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.

Details

Lead sponsor	Alcon Research
Phase	Phase 4
Status	COMPLETED
Enrolment	64
Start date	2008-09

Conditions

Cataract

Interventions

Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops

Primary outcomes

The Percentage of Patients With a Score of Zero for Anterior Chamber Cells. — Day 15 after cataract surgery
The percentage of patients with a score of zero for Anterior chamber cells. Anterior chamber inflammation was evaluated based on the number of cells per high-power field measured using the narrowest slit beam of the lamp (0.5 at a height of 8mm). Anterior chamber cells was recorded on a 0-4 point scale,0 = Less than 5 cells; 1 = Mild: 5-10 cells; 2 = Moderate:11-20 cells; 3 = Marked: 21-50 cells; 4 = Severe: Greater than 50 cells / hypopyon
The Percentage of Patients With no Ocular Pain — Day 15 after cataract surgery

Countries

United States